Improvement of meal‐related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan
Background The aim of this study is to clarify whether acotiamide and rabeprazole combination therapy can improve clinical symptoms, gastric emptying, and satisfaction with treatment in functional dyspepsia (FD) patients more effectively than acotiamide or rabeprazole monotherapy alone. We also aime...
Gespeichert in:
| Veröffentlicht in: | Neurogastroenterology and motility 2016-07, Vol.28 (7), p.1037-1047 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1047 |
|---|---|
| container_issue | 7 |
| container_start_page | 1037 |
| container_title | Neurogastroenterology and motility |
| container_volume | 28 |
| creator | Yamawaki, H. Futagami, S. Kawagoe, T. Maruki, Y. Hashimoto, S. Nagoya, H. Sato, H. Kodaka, Y. Gudis, K. Akamizu, T. Sakamoto, C. Iwakiri, K. |
| description | Background
The aim of this study is to clarify whether acotiamide and rabeprazole combination therapy can improve clinical symptoms, gastric emptying, and satisfaction with treatment in functional dyspepsia (FD) patients more effectively than acotiamide or rabeprazole monotherapy alone. We also aimed to determine whether acotiamide affects these changes via its effect on gastric emptying and appetite‐related hormones such as ghrelin.
Methods
We used Rome III criteria to evaluate upper abdominal symptoms and anxiety by the State‐Trait Anxiety Inventory (STAI). Gastric motility was evaluated by the 13C‐acetate breath test. Eighty‐one FD patients were treated with acotiamide (300 mg/day) (n = 35), acotiamide (300 mg/day) and rabeprazole (10 mg/day) (n = 28), or rabeprazole (10 mg/day) (n = 18) for a period of 4 weeks and followed after 4 weeks of no treatment. Adenocorticotropic hormone (ACTH), cortisol, leptin and ghrelin levels were measured in all FD patients.
Key Results
Acotiamide and rabeprazole combination therapy significantly improved postprandial distress syndrome (PDS)‐like symptoms (p = 0.018, p = 0.04 and p = 0.041, respectively) and epigastric pain (p = 0.024) as wells as STAI‐state scores (p = 0.04) compared to rabeprazole monotherapy. Both acotiamide monotherapy, and acotiamide taken in combination with rabeprazole, significantly (p = 0.001 and p = 0.02, respectively) improved satisfaction with treatment, compared to rabeprazole monotherapy. Acotiamide and rabeprazole combination therapy had no significant effect on ACTH and cortisol levels in FD patients. Of interest, acotiamide monotherapy, and acotiamide and rabeprazole combination therapy, significantly (p < 0.0001 and p = 0.018, respectively) increased acylated ghrelin/total ghrelin ratios and significantly (p = 0.04) improved impaired gastric emptying compared to rabeprazole monotherapy.
Conclusions & Inferences
Further studies are warranted to clarify how acotiamide treatment improves clinical symptoms in FD patients.
We aimed to clarify whether acotiamide and rabeprazole combination therapy significantly improves clinical symptoms and satisfaction with treatment via its effect on gastric emptying and appetite‐related hormones such as ghrelin, compared to acotiamide or rabeprazole monotherapy. Acotiamide and rabeprazole combination therapy significantly improved PDS‐like symptoms and epigastric pain and STAI‐state scores compared to rabeprazole monotherapy. Acotiamide monotherapy, and a |
| doi_str_mv | 10.1111/nmo.12805 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1808733126</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4098751571</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4565-d226711ac4bf3d0065af603da72d31622ea6dc08d97bc3e362d9e46a59148d373</originalsourceid><addsrcrecordid>eNqFkc1u1TAQhSNERUthwQsgS2zo4rb-SZx4iSooRS3dwDqaa09aV3EcbKdX2fEIfZG-FE-C701BCAlhWbIlfz5nZk5RvGL0mOV1Mjh_zHhDqyfFAROyWnHV8Kfbe0VXTPFqv3ge4y2lVPJSPiv2uVScqlIdFA_nbgz-Dh0OifiOOIT-x_f7gD0kNCTObkzeRQKDITjaa4gpWE1GsAPJe4Rk889INjbdkG4adLJ-gJ6YOY44RgskBdxJ7QjQPllw1iDZQFaN0Wv75_O8-F7f5Aqyfo932Met0ycYYXhR7HXQR3z5eB4WXz-8_3L6cXVxdXZ--u5ipcsqt284lzVjoMt1J0zuuoJOUmGg5kYwyTmCNJo2RtVrLVBIbhSWEirFysaIWhwWbxfdPJtvE8bUOhs19j0M6KfYsoY2tRCMy_-jtVKVzKYso2_-Qm_9FPK0Forl0rnI1NFC6eBjDNi1Y7AOwtwy2m7jbnPc7S7uzL5-VJzWDs1v8le-GThZgI3tcf63Uvv58mqR_Am_2Lgu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1799156523</pqid></control><display><type>article</type><title>Improvement of meal‐related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><creator>Yamawaki, H. ; Futagami, S. ; Kawagoe, T. ; Maruki, Y. ; Hashimoto, S. ; Nagoya, H. ; Sato, H. ; Kodaka, Y. ; Gudis, K. ; Akamizu, T. ; Sakamoto, C. ; Iwakiri, K.</creator><creatorcontrib>Yamawaki, H. ; Futagami, S. ; Kawagoe, T. ; Maruki, Y. ; Hashimoto, S. ; Nagoya, H. ; Sato, H. ; Kodaka, Y. ; Gudis, K. ; Akamizu, T. ; Sakamoto, C. ; Iwakiri, K.</creatorcontrib><description>Background
The aim of this study is to clarify whether acotiamide and rabeprazole combination therapy can improve clinical symptoms, gastric emptying, and satisfaction with treatment in functional dyspepsia (FD) patients more effectively than acotiamide or rabeprazole monotherapy alone. We also aimed to determine whether acotiamide affects these changes via its effect on gastric emptying and appetite‐related hormones such as ghrelin.
Methods
We used Rome III criteria to evaluate upper abdominal symptoms and anxiety by the State‐Trait Anxiety Inventory (STAI). Gastric motility was evaluated by the 13C‐acetate breath test. Eighty‐one FD patients were treated with acotiamide (300 mg/day) (n = 35), acotiamide (300 mg/day) and rabeprazole (10 mg/day) (n = 28), or rabeprazole (10 mg/day) (n = 18) for a period of 4 weeks and followed after 4 weeks of no treatment. Adenocorticotropic hormone (ACTH), cortisol, leptin and ghrelin levels were measured in all FD patients.
Key Results
Acotiamide and rabeprazole combination therapy significantly improved postprandial distress syndrome (PDS)‐like symptoms (p = 0.018, p = 0.04 and p = 0.041, respectively) and epigastric pain (p = 0.024) as wells as STAI‐state scores (p = 0.04) compared to rabeprazole monotherapy. Both acotiamide monotherapy, and acotiamide taken in combination with rabeprazole, significantly (p = 0.001 and p = 0.02, respectively) improved satisfaction with treatment, compared to rabeprazole monotherapy. Acotiamide and rabeprazole combination therapy had no significant effect on ACTH and cortisol levels in FD patients. Of interest, acotiamide monotherapy, and acotiamide and rabeprazole combination therapy, significantly (p < 0.0001 and p = 0.018, respectively) increased acylated ghrelin/total ghrelin ratios and significantly (p = 0.04) improved impaired gastric emptying compared to rabeprazole monotherapy.
Conclusions & Inferences
Further studies are warranted to clarify how acotiamide treatment improves clinical symptoms in FD patients.
We aimed to clarify whether acotiamide and rabeprazole combination therapy significantly improves clinical symptoms and satisfaction with treatment via its effect on gastric emptying and appetite‐related hormones such as ghrelin, compared to acotiamide or rabeprazole monotherapy. Acotiamide and rabeprazole combination therapy significantly improved PDS‐like symptoms and epigastric pain and STAI‐state scores compared to rabeprazole monotherapy. Acotiamide monotherapy, and acotiamide and rabeprazole combination therapy significantly increased acylated ghrelin/total ghrelin ratios and significantly improved impaired gastric emptying compared to rabeprazole monotherapy.</description><identifier>ISSN: 1350-1925</identifier><identifier>EISSN: 1365-2982</identifier><identifier>DOI: 10.1111/nmo.12805</identifier><identifier>PMID: 26920949</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Abdominal Pain - blood ; Abdominal Pain - drug therapy ; Abdominal Pain - epidemiology ; acotiamide ; Acylation ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Benzamides - administration & dosage ; Biomarkers - blood ; Drug Therapy, Combination ; Dyspepsia - blood ; Dyspepsia - drug therapy ; Dyspepsia - epidemiology ; Female ; functional dyspepsia ; gastric motility ; Gastrointestinal Agents - administration & dosage ; ghrelin ; Ghrelin - blood ; Humans ; Japan - epidemiology ; Male ; Meals - drug effects ; Meals - physiology ; meal‐related symptoms ; Middle Aged ; Postprandial Period - drug effects ; Postprandial Period - physiology ; Prospective Studies ; rabeprazole ; Rabeprazole - administration & dosage ; Thiazoles - administration & dosage ; Treatment Outcome ; Young Adult</subject><ispartof>Neurogastroenterology and motility, 2016-07, Vol.28 (7), p.1037-1047</ispartof><rights>2016 John Wiley & Sons Ltd</rights><rights>2016 John Wiley & Sons Ltd.</rights><rights>Copyright © 2016 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4565-d226711ac4bf3d0065af603da72d31622ea6dc08d97bc3e362d9e46a59148d373</citedby><cites>FETCH-LOGICAL-c4565-d226711ac4bf3d0065af603da72d31622ea6dc08d97bc3e362d9e46a59148d373</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fnmo.12805$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fnmo.12805$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26920949$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamawaki, H.</creatorcontrib><creatorcontrib>Futagami, S.</creatorcontrib><creatorcontrib>Kawagoe, T.</creatorcontrib><creatorcontrib>Maruki, Y.</creatorcontrib><creatorcontrib>Hashimoto, S.</creatorcontrib><creatorcontrib>Nagoya, H.</creatorcontrib><creatorcontrib>Sato, H.</creatorcontrib><creatorcontrib>Kodaka, Y.</creatorcontrib><creatorcontrib>Gudis, K.</creatorcontrib><creatorcontrib>Akamizu, T.</creatorcontrib><creatorcontrib>Sakamoto, C.</creatorcontrib><creatorcontrib>Iwakiri, K.</creatorcontrib><title>Improvement of meal‐related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan</title><title>Neurogastroenterology and motility</title><addtitle>Neurogastroenterol Motil</addtitle><description>Background
The aim of this study is to clarify whether acotiamide and rabeprazole combination therapy can improve clinical symptoms, gastric emptying, and satisfaction with treatment in functional dyspepsia (FD) patients more effectively than acotiamide or rabeprazole monotherapy alone. We also aimed to determine whether acotiamide affects these changes via its effect on gastric emptying and appetite‐related hormones such as ghrelin.
Methods
We used Rome III criteria to evaluate upper abdominal symptoms and anxiety by the State‐Trait Anxiety Inventory (STAI). Gastric motility was evaluated by the 13C‐acetate breath test. Eighty‐one FD patients were treated with acotiamide (300 mg/day) (n = 35), acotiamide (300 mg/day) and rabeprazole (10 mg/day) (n = 28), or rabeprazole (10 mg/day) (n = 18) for a period of 4 weeks and followed after 4 weeks of no treatment. Adenocorticotropic hormone (ACTH), cortisol, leptin and ghrelin levels were measured in all FD patients.
Key Results
Acotiamide and rabeprazole combination therapy significantly improved postprandial distress syndrome (PDS)‐like symptoms (p = 0.018, p = 0.04 and p = 0.041, respectively) and epigastric pain (p = 0.024) as wells as STAI‐state scores (p = 0.04) compared to rabeprazole monotherapy. Both acotiamide monotherapy, and acotiamide taken in combination with rabeprazole, significantly (p = 0.001 and p = 0.02, respectively) improved satisfaction with treatment, compared to rabeprazole monotherapy. Acotiamide and rabeprazole combination therapy had no significant effect on ACTH and cortisol levels in FD patients. Of interest, acotiamide monotherapy, and acotiamide and rabeprazole combination therapy, significantly (p < 0.0001 and p = 0.018, respectively) increased acylated ghrelin/total ghrelin ratios and significantly (p = 0.04) improved impaired gastric emptying compared to rabeprazole monotherapy.
Conclusions & Inferences
Further studies are warranted to clarify how acotiamide treatment improves clinical symptoms in FD patients.
We aimed to clarify whether acotiamide and rabeprazole combination therapy significantly improves clinical symptoms and satisfaction with treatment via its effect on gastric emptying and appetite‐related hormones such as ghrelin, compared to acotiamide or rabeprazole monotherapy. Acotiamide and rabeprazole combination therapy significantly improved PDS‐like symptoms and epigastric pain and STAI‐state scores compared to rabeprazole monotherapy. Acotiamide monotherapy, and acotiamide and rabeprazole combination therapy significantly increased acylated ghrelin/total ghrelin ratios and significantly improved impaired gastric emptying compared to rabeprazole monotherapy.</description><subject>Abdominal Pain - blood</subject><subject>Abdominal Pain - drug therapy</subject><subject>Abdominal Pain - epidemiology</subject><subject>acotiamide</subject><subject>Acylation</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Benzamides - administration & dosage</subject><subject>Biomarkers - blood</subject><subject>Drug Therapy, Combination</subject><subject>Dyspepsia - blood</subject><subject>Dyspepsia - drug therapy</subject><subject>Dyspepsia - epidemiology</subject><subject>Female</subject><subject>functional dyspepsia</subject><subject>gastric motility</subject><subject>Gastrointestinal Agents - administration & dosage</subject><subject>ghrelin</subject><subject>Ghrelin - blood</subject><subject>Humans</subject><subject>Japan - epidemiology</subject><subject>Male</subject><subject>Meals - drug effects</subject><subject>Meals - physiology</subject><subject>meal‐related symptoms</subject><subject>Middle Aged</subject><subject>Postprandial Period - drug effects</subject><subject>Postprandial Period - physiology</subject><subject>Prospective Studies</subject><subject>rabeprazole</subject><subject>Rabeprazole - administration & dosage</subject><subject>Thiazoles - administration & dosage</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>1350-1925</issn><issn>1365-2982</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1u1TAQhSNERUthwQsgS2zo4rb-SZx4iSooRS3dwDqaa09aV3EcbKdX2fEIfZG-FE-C701BCAlhWbIlfz5nZk5RvGL0mOV1Mjh_zHhDqyfFAROyWnHV8Kfbe0VXTPFqv3ge4y2lVPJSPiv2uVScqlIdFA_nbgz-Dh0OifiOOIT-x_f7gD0kNCTObkzeRQKDITjaa4gpWE1GsAPJe4Rk889INjbdkG4adLJ-gJ6YOY44RgskBdxJ7QjQPllw1iDZQFaN0Wv75_O8-F7f5Aqyfo932Met0ycYYXhR7HXQR3z5eB4WXz-8_3L6cXVxdXZ--u5ipcsqt284lzVjoMt1J0zuuoJOUmGg5kYwyTmCNJo2RtVrLVBIbhSWEirFysaIWhwWbxfdPJtvE8bUOhs19j0M6KfYsoY2tRCMy_-jtVKVzKYso2_-Qm_9FPK0Forl0rnI1NFC6eBjDNi1Y7AOwtwy2m7jbnPc7S7uzL5-VJzWDs1v8le-GThZgI3tcf63Uvv58mqR_Am_2Lgu</recordid><startdate>201607</startdate><enddate>201607</enddate><creator>Yamawaki, H.</creator><creator>Futagami, S.</creator><creator>Kawagoe, T.</creator><creator>Maruki, Y.</creator><creator>Hashimoto, S.</creator><creator>Nagoya, H.</creator><creator>Sato, H.</creator><creator>Kodaka, Y.</creator><creator>Gudis, K.</creator><creator>Akamizu, T.</creator><creator>Sakamoto, C.</creator><creator>Iwakiri, K.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201607</creationdate><title>Improvement of meal‐related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan</title><author>Yamawaki, H. ; Futagami, S. ; Kawagoe, T. ; Maruki, Y. ; Hashimoto, S. ; Nagoya, H. ; Sato, H. ; Kodaka, Y. ; Gudis, K. ; Akamizu, T. ; Sakamoto, C. ; Iwakiri, K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4565-d226711ac4bf3d0065af603da72d31622ea6dc08d97bc3e362d9e46a59148d373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Abdominal Pain - blood</topic><topic>Abdominal Pain - drug therapy</topic><topic>Abdominal Pain - epidemiology</topic><topic>acotiamide</topic><topic>Acylation</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Benzamides - administration & dosage</topic><topic>Biomarkers - blood</topic><topic>Drug Therapy, Combination</topic><topic>Dyspepsia - blood</topic><topic>Dyspepsia - drug therapy</topic><topic>Dyspepsia - epidemiology</topic><topic>Female</topic><topic>functional dyspepsia</topic><topic>gastric motility</topic><topic>Gastrointestinal Agents - administration & dosage</topic><topic>ghrelin</topic><topic>Ghrelin - blood</topic><topic>Humans</topic><topic>Japan - epidemiology</topic><topic>Male</topic><topic>Meals - drug effects</topic><topic>Meals - physiology</topic><topic>meal‐related symptoms</topic><topic>Middle Aged</topic><topic>Postprandial Period - drug effects</topic><topic>Postprandial Period - physiology</topic><topic>Prospective Studies</topic><topic>rabeprazole</topic><topic>Rabeprazole - administration & dosage</topic><topic>Thiazoles - administration & dosage</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamawaki, H.</creatorcontrib><creatorcontrib>Futagami, S.</creatorcontrib><creatorcontrib>Kawagoe, T.</creatorcontrib><creatorcontrib>Maruki, Y.</creatorcontrib><creatorcontrib>Hashimoto, S.</creatorcontrib><creatorcontrib>Nagoya, H.</creatorcontrib><creatorcontrib>Sato, H.</creatorcontrib><creatorcontrib>Kodaka, Y.</creatorcontrib><creatorcontrib>Gudis, K.</creatorcontrib><creatorcontrib>Akamizu, T.</creatorcontrib><creatorcontrib>Sakamoto, C.</creatorcontrib><creatorcontrib>Iwakiri, K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Neurogastroenterology and motility</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamawaki, H.</au><au>Futagami, S.</au><au>Kawagoe, T.</au><au>Maruki, Y.</au><au>Hashimoto, S.</au><au>Nagoya, H.</au><au>Sato, H.</au><au>Kodaka, Y.</au><au>Gudis, K.</au><au>Akamizu, T.</au><au>Sakamoto, C.</au><au>Iwakiri, K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improvement of meal‐related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan</atitle><jtitle>Neurogastroenterology and motility</jtitle><addtitle>Neurogastroenterol Motil</addtitle><date>2016-07</date><risdate>2016</risdate><volume>28</volume><issue>7</issue><spage>1037</spage><epage>1047</epage><pages>1037-1047</pages><issn>1350-1925</issn><eissn>1365-2982</eissn><abstract>Background
The aim of this study is to clarify whether acotiamide and rabeprazole combination therapy can improve clinical symptoms, gastric emptying, and satisfaction with treatment in functional dyspepsia (FD) patients more effectively than acotiamide or rabeprazole monotherapy alone. We also aimed to determine whether acotiamide affects these changes via its effect on gastric emptying and appetite‐related hormones such as ghrelin.
Methods
We used Rome III criteria to evaluate upper abdominal symptoms and anxiety by the State‐Trait Anxiety Inventory (STAI). Gastric motility was evaluated by the 13C‐acetate breath test. Eighty‐one FD patients were treated with acotiamide (300 mg/day) (n = 35), acotiamide (300 mg/day) and rabeprazole (10 mg/day) (n = 28), or rabeprazole (10 mg/day) (n = 18) for a period of 4 weeks and followed after 4 weeks of no treatment. Adenocorticotropic hormone (ACTH), cortisol, leptin and ghrelin levels were measured in all FD patients.
Key Results
Acotiamide and rabeprazole combination therapy significantly improved postprandial distress syndrome (PDS)‐like symptoms (p = 0.018, p = 0.04 and p = 0.041, respectively) and epigastric pain (p = 0.024) as wells as STAI‐state scores (p = 0.04) compared to rabeprazole monotherapy. Both acotiamide monotherapy, and acotiamide taken in combination with rabeprazole, significantly (p = 0.001 and p = 0.02, respectively) improved satisfaction with treatment, compared to rabeprazole monotherapy. Acotiamide and rabeprazole combination therapy had no significant effect on ACTH and cortisol levels in FD patients. Of interest, acotiamide monotherapy, and acotiamide and rabeprazole combination therapy, significantly (p < 0.0001 and p = 0.018, respectively) increased acylated ghrelin/total ghrelin ratios and significantly (p = 0.04) improved impaired gastric emptying compared to rabeprazole monotherapy.
Conclusions & Inferences
Further studies are warranted to clarify how acotiamide treatment improves clinical symptoms in FD patients.
We aimed to clarify whether acotiamide and rabeprazole combination therapy significantly improves clinical symptoms and satisfaction with treatment via its effect on gastric emptying and appetite‐related hormones such as ghrelin, compared to acotiamide or rabeprazole monotherapy. Acotiamide and rabeprazole combination therapy significantly improved PDS‐like symptoms and epigastric pain and STAI‐state scores compared to rabeprazole monotherapy. Acotiamide monotherapy, and acotiamide and rabeprazole combination therapy significantly increased acylated ghrelin/total ghrelin ratios and significantly improved impaired gastric emptying compared to rabeprazole monotherapy.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>26920949</pmid><doi>10.1111/nmo.12805</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1350-1925 |
| ispartof | Neurogastroenterology and motility, 2016-07, Vol.28 (7), p.1037-1047 |
| issn | 1350-1925 1365-2982 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1808733126 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content |
| subjects | Abdominal Pain - blood Abdominal Pain - drug therapy Abdominal Pain - epidemiology acotiamide Acylation Adolescent Adult Aged Aged, 80 and over Benzamides - administration & dosage Biomarkers - blood Drug Therapy, Combination Dyspepsia - blood Dyspepsia - drug therapy Dyspepsia - epidemiology Female functional dyspepsia gastric motility Gastrointestinal Agents - administration & dosage ghrelin Ghrelin - blood Humans Japan - epidemiology Male Meals - drug effects Meals - physiology meal‐related symptoms Middle Aged Postprandial Period - drug effects Postprandial Period - physiology Prospective Studies rabeprazole Rabeprazole - administration & dosage Thiazoles - administration & dosage Treatment Outcome Young Adult |
| title | Improvement of meal‐related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T19%3A58%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improvement%20of%20meal%E2%80%90related%20symptoms%20and%20epigastric%20pain%20in%20patients%20with%20functional%20dyspepsia%20treated%20with%20acotiamide%20was%20associated%20with%20acylated%20ghrelin%20levels%20in%20Japan&rft.jtitle=Neurogastroenterology%20and%20motility&rft.au=Yamawaki,%20H.&rft.date=2016-07&rft.volume=28&rft.issue=7&rft.spage=1037&rft.epage=1047&rft.pages=1037-1047&rft.issn=1350-1925&rft.eissn=1365-2982&rft_id=info:doi/10.1111/nmo.12805&rft_dat=%3Cproquest_cross%3E4098751571%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1799156523&rft_id=info:pmid/26920949&rfr_iscdi=true |